Topical foscarnet (PFA) and acyclovir (ACV) were compared in the dorsal cutaneous guinea pig model of herpes simplex virus type 1 infection. The relative order of efficacy was PFA cream>ACV cream>ACV ointment. In vitro studies demonstrated that PFA and ACV formulated in cream vehicles penetrated through guinea pig skin 7-to 10-fold faster than did ACV in ointment.
efficacy between each of the four different antiviral formulations. The severity of the infection at each treatment site was evaluated on the day after completion of the treatment regimen by examining the number of lesions, the diameter of lesions, the total lesion area, and the quantity of virus in excised skin. Further details of these procedures have been previously described (8, 22 Full-thickness dorsal guinea pig skin was excised, and a portion of the skin was clamped across a Franz singlechambered glass diffusion cell (Crown Glass Co., Sommerville, N.J. (8, 22, 23) .
Lesion severity between drug and vehicle control-treated sites were compared by the Wilcoxon signed-rank test. The percent efficacies of different drug formulations were compared by the Mann-Whitney rank-sum procedure and in vitro flux values by Student's t test. All probability determinations were two tailed, and a P of c 0.05 was considered to be significant.
The results of the in vivo studies are shown in Table 1 . Compared with lesion severity at vehicle control-treated sites, reductions of the mean number of lesions by 3% PFA, 0.3% PFA, ACV cream, and ACV ointment were 54, 36, 19, and -8%, respectively; reductions in the mean lesion area were 73, 52, 31, and 19%; and the reductions in mean lesion virus titer effected by these treatments were 90, 80, 75, and 60%. The greater reduction in number of lesions by 3% PFA, 0.3% PFA, and ACV cream compared with that of ACV ointment was statistically significant (P c 0.03). Both 3% and 0.3% PFA were significantly more effective in reducing lesion area than was ACV ointment or ACV cream (P c 0.05). PFA (3%) had a significantly greater effect on lesion virus titer than did ACV ointment (P = 0.03).
The penetration of 0.3% PFA from cream formulation through excised guinea pig skin is compared with prior data (9) on the skin penetration of 5% ACV in cream and in ointment (Fig. 1) . The mean fluxes + standard error of the mean of 0.3% PFA (0.51 + 0.13 pLg/cm2 per h) and 5% ACV (0.36 ± 0.12 [Lg/cm2 per h) from cream formulation were similar (P > 0.4) and were significantly greater than the flux of 5% ACV from ointment formulation (0.05 + 0.01 ILg/cm2 per h, P < 0.05). ACV in cream exhibited a substantially longer lag period than did PFA before achieving steady-state penetration kinetics (Fig. 1) . The present studies demonstrate that the relative order of efficacy of the different formulations was as follows: 3% PFA cream>0.3% PFA cream>ACV cream>ACV ointment. These findings show that topical PFA cream is more effective in the cutaneous guinea pig model than ACV cream, and we confirm prior reports that topical PFA cream (1) and ACV cream (2) are superior to ACV ointment in this experimental system. Our in vitro skin penetration studies indicate that the better results with topical PFA cream and ACV cream compared with ACV ointment are likely because of better drug delivery by the cream preparations.
The superior effect of PFA over ACV cream in our Lastly, although the steady-state rates of drug flux of 0.3% PFA and 5% ACV cream were similar in the present study, penetration of ACV was markedly delayed, which could have adversely affected the in vivo activity of this formulation. The minimal efficacy of topical ACV ointment in the present studies (19% reduction in lesion area) and in other experiments (8, 22, 23) parallels the disappointing results with this preparation in recurrent cutaneous human HSV infections in normal hosts (3, 17, 20, 21, 24, 27) . Similarly, the better results (31 to 73% reduction in lesion area) seen with topical PFA and topical ACV cream in our model system find parallels in the recent clinical reports which indicate that these formulations may be more effective than ACV ointment (6, 7, 15, 19, (25) (26) (27) . The human experience does not support superiority of topical PFA over ACV cream, as was found in the guinea pig. This may be due to therapeutic limitations in recurrent human herpes simplex disease; i.e., greater antiviral activity is unable to produce a better clinical result. Alternatively, there may be important differences in drug metabolism or competitive substrate concentrations (12) between human and guinea pig skin that influence antiviral activity. While there does not appear to be a difference in the penetration of ACV through human versus guinea pig skin (9), the rate of penetration of PFA through human skin has not been examined. 
